Lux Biosciences has increased its $36 million first round of venture capital by $13 million, bring the total round to $49 million. New investor Prospect Venture partners kicked in $12 million, with the rest coming from HBM Partner, Novo and SV Life Sciences. The company targets ophthalmic diseases such as Uveitis, Dry Eye Syndrome and Age-Related Macular Degeneration. The company's lead product is LX-211, a Phase III compound licensed from Isotechnika.
- check out this press release
PLUS: Device maker EnteroMedics has landed $45.2 million in its third round. The company makes devices for the treatment of obesity and gastrointestinal disorders. Release